

TABLE OF CONTENTS

- 1 **Criminalistics—Introduction to Controlled Substances** *Joseph P. Bono*
- 2 **Pathology of Drug Abuse** *Edited by Charles V. Wetli*
 - 2.1 **Preliminary Observations** *Charles V. Wetli*
 - 2.2 **Diseases of the Heart**
 - 2.2.1 **Techniques for Examination of the Heart** *Renu Virmani, Allen P. Burke, and Andrew Farb*
 - 2.2.2 **Myocardial Alterations in Drug Abusers** *Steven B. Karch*
 - 2.2.3 **Endocarditis** *Michael D. Bell*
 - 2.2.4 **Vascular Effects of Substance Abuse** *Frank D. Kolodgie, Allen Burke, Jagat Narula, Florabel G. Mullick, and Renu Virmani*
 - 2.3 **Lung Disease** *Michael D. Bell*
 - 2.4 **Disorders of the Central Nervous System** *Michael D. Bell*
 - 2.5 **Miscellaneous Complications** *Charles V. Wetli*
- 3 **Pharmacokinetics: Drug Absorption, Distribution, and Elimination** *Amanda J. Jenkins, and Edward J. Cone*
- 4 **Pharmacodynamics** *Edited by Stephen J. Heishman*
 - 4.1 **Effects of Abused Drugs on Human Performance: Laboratory Assessment** *Stephen J. Heishman*
 - 4.2 **Performance Measures of Behavioral Impairment in Applied Settings** *Thomas H. Kelly, Richard C. Taylor, Stephen J. Heishman, and Dennis J. Crouch*
 - 4.3 **Effects of Abused Drugs on Pupillary Size and the Light Reflex** *Wallace B. Pickworth, Reginald V. Fant, and Edward B. Bunker*
 - 4.4 **Evaluating Abuse Liability: Methods and Predictive Value** *Kenzie L. Preston, and Sharon L. Walsh*
- 5 **Alcohol** *Edited by Christopher S. Martin*
 - 5.1 **Measuring Acute Alcohol Impairment** *Christopher S. Martin*
 - 5.2 **Measuring Blood-Alcohol Concentration for Clinical and Forensic Purposes** *A. Wayne Jones and Derrick J. Pounder*
 - 5.3 **Measuring Alcohol Postmortem** *Derrick J. Pounder and A. Wayne Jones*
 - 5.4 **Biochemical Tests for Acute and Chronic Alcohol Ingestion** *Anders Helander and Alan Wayne Jones*
- 6 **Neurochemistry of Drug Abuse** *Edited by Deborah C. Mash and Julie K. Staley*
 - 6.1 **The Dopamine Transporter and Addiction** *John W. Boja and William M. Meil*
 - 6.2 **Neuropsychiatric Consequences of Chronic Cocaine Abuse** *Deborah C. Mash*
 - 6.3 **Neurochemical Adaptations and Cocaine Dependence** *Julie K. Staley*
 - 6.4 **The Neurobiology of Relapse** *David W. Self*

-
- 6.5 Serotonergic Dysfunction During Cocaine Withdrawal: Implications for Cocaine-Induced Depression *Michael H. Baumann and Richard B. Rothman*
 - 6.6 Neurochemistry of Psychedelic Drugs *J.C. Callaway and D.J. McKenna*
 - 7 Addiction Medicine *Edited by Kim Wolff*
 - 7.1 The Principles of Addiction Medicine *Duncan Raistrick*
 - 7.2 Substitute Prescribing *Kim Wolff*
 - 7.2.1.6 Buprenorphine Maintenance Prescribing *Douglas Fraser*
 - 7.3 Treatment of Withdrawal Syndromes *Joanna Banbery*
 - 7.4 Replacement Prescribing *Kim Wolff*
 - 7.4.1 Opiate Specific Prescribing *Douglas Fraser*
 - 7.5 Management of Comorbidity *Duncan Raistrick*
 - 7.6 Toxicologic Issues *Alastair W.M. Hay*
 - 8 Medical Complications of Drug Abuse *Edited by Neal L. Benowitz*
 - 8.1 Drug-Related Syndromes *Shoshana Zevin and Neal L. Benowitz*
 - 8.2 Emergency Management of Drug Abuse-Related Disorders *Brett A. Roth, Neal L. Benowitz, and Kent R. Olson*
 - 9 Sports *Edited by Jordi Segura*
 - 9.1 Introduction *Jordi Segura*
 - 9.2 Specific Agents *Rafael de la Torre*
 - 9.3 Anabolic Androgenic Steroids *Don H. Catlin*
 - 9.4 Detection of Exogenous Anabolic Androgenic Steroids *Wilhelm Schänzer*
 - 9.5 Growth Hormone Abuse in Elite Athletes *Ross C. Cuneo, Jennifer D. Wallace, and Peter Sönksen*
 - 9.6 Erythropoietin *Björn Ekblom*
 - 9.7 Summary of International Olympic Committee Regulations *Jordi Segura*
 - 10 Workplace Testing *Edited by Yale H. Caplan*
 - 10.1 Development and Scope of Regulated Testing *J. Michael Walsh*
 - 10.2 Laboratory Accreditation Programs
 - 10.2.1 An Overview of the Mandatory Guidelines for Federal Workplace Drug Testing Programs *Donna M. Bush*
 - 10.2.2 The College of American Pathologists Voluntary Laboratory Accreditation Program *John Baenziger*
 - 10.3 Analytical Considerations and Approaches for Drugs *Michael Peat and Alan E. Davis*
 - 10.4 Urine Specimen Suitability for Drug Testing *Ruth E. Winecker and Bruce A. Goldberger*
 - 10.5 The Role of the Medical Review Officer: Current Issues *Steven St. Clair*
 - 10.6 Alternative Drugs, Specimens, and Approaches for Non-Regulated Drug Testing *Dennis Crouch*
 - 10.7 Implementation of Alcohol Testing: General Considerations and Processes *Donna R. Smith*
 - 11 Alternative Testing Matrices *Marilyn A. Huestis and Edward J. Cone*
 - 12 Postmortem Toxicology *Edited by Wm. Lee Hearn*
 - 12.1 Introduction of Postmortem Toxicology *Wm. Lee Hearn and H. Chip Walls*
-

-
- 12.2 Specimen Selection, Collection, Preservation, and Security
Bradford R. Hepler and Daniel S. Isenschmid
 - 12.3 Common Methods in Postmortem Toxicology *Wm. Lee Hearn and
H. Chip Walls*
 - 12.4 Strategies for Postmortem Toxicology Investigation *Wm. Lee Hearn and
H. Chip Walls*
 - 12.5 Quality Assurance in Postmortem Toxicology *Wilmo Andollo*
 - 12.6 Interpretation of Postmortem Drug Levels *Graham R. Jones*

13 Drug Law

- 13.1 Current Legal Issues of Workplace Drug Testing *Theodore F. Shults*
- 13.2 DUI Defenses *Alan Wayne Jones and Barry Logan*
- 13.3 Fetal Rights *Stephen M. Mohaupt*

Appendices

- Ia Glossary of Terms in Forensic Toxicology *Chip Walls*
- Ib Common Abbreviations *Chip Walls*
- Ic References for Methods of Drug Quantitative Analysis
- II Sample Calculations *Barry K. Logan and Alan Wayne Jones*
- III Predicted Normal Heart Weight (g) as a Function of Body Height

CHAPTER 1

CRIMINALISTICS—INTRODUCTION TO CONTROLLED SUBSTANCES

JOSEPH P. BONO, MA

SUPERVISORY CHEMIST, DRUG ENFORCEMENT ADMINISTRATION, SPECIAL TESTING AND
RESEARCH LABORATORY, MCLEAN, VIRGINIA

TABLE OF CONTENTS

- 1.1 *Definition and Scheduling of Controlled Substances*
- 1.2 *Scheduling of Controlled Substances*
- 1.3 *Controlled Substance Analogue Enforcement Act of 1986*
- 1.4 *Controlled Substances*
 - 1.4.1 *Heroin*
 - 1.4.1.1 *Heroin Sources by Region*
 - 1.4.1.2 *Isolation of Morphine and Heroin Production*
 - 1.4.2 *Cocaine*
 - 1.4.2.1 *Sources of Cocaine*
 - 1.4.2.2 *Historical Considerations*
 - 1.4.2.3 *Isolation and Purification*
 - 1.4.2.4 *Conversion to “Crack”*
 - 1.4.2.5 *Other Coca Alkaloids*
 - 1.4.2.6 *Cocaine Adulterants*
 - 1.4.3 *Marijuana*
 - 1.4.3.1 *History and Terminology*
 - 1.4.3.2 *Laboratory Analysis*
 - 1.4.4 *Peyote*
 - 1.4.5 *Psilocybin Mushrooms*
 - 1.4.6 *Lysergic Acid Diethylamide (LSD)*
 - 1.4.7 *Phencyclidine (PCP)*
 - 1.4.8 *Fentanyl*
 - 1.4.9 *Phenethylamines*
 - 1.4.10 *Methcathinone (CAT)*
 - 1.4.11 *Catha Edulis (KHAT)*
 - 1.4.12 *Anabolic Steroids*
 - 1.4.12.1 *Regulatory History*
 - 1.4.12.2 *Structure Activity Relationship*
 - 1.4.12.3 *Forensic Analysis*
- 1.5 *Legitimate Pharmaceutical Preparations*
 - 1.5.1 *Benzodiazepines*
 - 1.5.2 *Other Central Nervous System Depressants*

- 1.5.3 *Narcotic Analgesics*
- 1.5.4 *Central Nervous System Stimulants*
- 1.5.5 *Identifying Generic Products*
- 1.6 *Unique Identify Factors*
 - 1.6.1 *Packaging Logos*
 - 1.6.2 *Tablet Markings and Capsule Imprints*
 - 1.6.3 *Blotter Paper LSD*
- 1.7 *Analyzing Drugs in the Forensic Science Laboratory*
 - 1.7.1 *Screening Tests*
 - 1.7.1.1 *Physical Characteristics*
 - 1.7.1.2 *Color Tests*
 - 1.7.1.3 *Thin Layer Chromatography*
 - 1.7.2 *Confirmatory Chemical Tests*
 - 1.7.2.1 *Microcrystal Identifications*
 - 1.7.2.2 *Gas Chromatography*
 - 1.7.2.3 *High Performance Liquid Chromatography (HPLC)*
 - 1.7.2.4 *Capillary Electrophoresis (CE)*
 - 1.7.2.5 *Infrared Spectrophotometry (IR)*
 - 1.7.2.6 *Gas Chromatography/Mass Spectroscopy (GC/MS)*
 - 1.7.2.7 *Nuclear Magnetic Resonance (NMR) Spectroscopy*
 - 1.7.3 *Controlled Substances Examinations*
 - 1.7.3.1 *Identifying and Quantitating Controlled Substances*
 - 1.7.3.2 *Identifying Adulterants and Diluents*
 - 1.7.3.3 *Quantitating Controlled Substances*
 - 1.7.3.4 *Reference Standards*
- 1.8 *Comparative Analysis*
 - 1.8.1 *Determining Commonality of Source*
 - 1.8.2 *Comparing Heroin Exhibits*
 - 1.8.3 *Comparing Cocaine Exhibits*
- 1.9 *Clandestine Laboratories*
 - 1.9.1 *Safety Concerns*
 - 1.9.2 *Commonly Encountered Chemicals in the Clandestine Laboratory*
 - 1.9.3 *Tables of Controlled Substances*
 - 1.9.3.1 *Generalized List by Category of Physiological Effects and Medical Uses of Controlled Substances*
 - 1.9.3.2 *Listing of Controlled Substances by Schedule Number*

1.1 DEFINITION AND SCHEDULING OF CONTROLLED SUBSTANCES

A “controlled substance” is a drug or substance of which the use, sale, or distribution is regulated by the federal government or a state government entity. These controlled substances are listed specifically or by classification on the federal level in the Controlled Substances Act (CSA) or in Part 1308 of the Code of Federal Regulations. The purpose of the CSA is to minimize the quantity of useable substances available to those who are likely to abuse them. At the same time, the CSA provides for the legitimate medical, scientific, and industrial needs of these substances in the U.S.